Results 161 to 170 of about 234,859 (336)
Objective Keratinocyte‐derived interferon kappa (IFN‐κ) is chronically overexpressed in human non‐lesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFN‐κ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein +14 more
wiley +1 more source
Histamine, eosinophils and basophils in the blood
Charles F. Code, Ross G. Mitchell
openalex +2 more sources
Eosinophils in the rectal mucosa. A simple method of predicting the outcome of ulcerative proctocolitis? [PDF]
R V Heatley, P D James
openalex +1 more source
Objective The Phase 3 MANDARA study demonstrated non‐inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair +14 more
wiley +1 more source
Comparison of intracellular bactericidal activities of human neutrophils and eosinophils [PDF]
LR DeChatelet +5 more
openalex +1 more source
Eosinophil and neutrophil colony-forming cells in culture [PDF]
C Dao, D Metcalf, G Bilski-Pasquier
openalex +1 more source
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl +11 more
wiley +1 more source
Effects of in vivo prednisone on in vitro eosinophil and neutrophil adherence and chemotaxis [PDF]
Robert A. Clark, JI Gallin, AS Fauci
openalex +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source

